drugset / Trial / NCT01660295

Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

NCT01660295

Phase 1/2 Completed 32 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.

Timeline

Start
2011-12
Primary completion
2012-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Certoparin Other / unclassified 3000 iu Subcutaneous
Subject Certoparin Other / unclassified 8000 iu Subcutaneous